Evaluation Of HUK in Acute Stroke Patients: MRS and CTP

A)Specific Primary Objective:

• To determine if HUK, administered within 72 hours of AIS onset is superior to regular treatment in improving NAA values and CBF on day 14 post stroke.

B) Specific Secondary Objectives:

• To determine if HUK, administered within 72 hours of AIS onset is superior to regular treatment in reducing neurological deficit and improving functional outcome on day 14 post stroke.

Recruitment of study subjects:

Acute ischemic stroke patients admitted to the Neurology department in XWh (Xuan hospital) during the study period who are eligible to participate in this study based on criteria stated above will be invited to participate in this study.

The time window for enrolment will be within 72 hours of symptom onset. All eligible patients will be identified by the ward and on-call Neurology/Medical teams and referred to the study research assistants or investigators; who will then screen the patient for participation in this trial.

STUDY INTERVENTION The assigned treatment 0.15 PNA units of HUK injection or regular treatment will be administered once daily for 14 consecutive days soon after informed consent is taken and the patient is enrolled into the study.

Follow-up Assessment:

The neurologic deficits, global functional abilities and level of handicap will be scored using the NIH Stroke Scale (NIHSS) and the modified Rankin scale (mRS) at baseline and on day 14(plus or minus 14 days).

Inclusion criteria

• ages ranging from 18 to 80 years
• onset time less than 72 h, NIHSS score ≥4;

Exclusion criteria

• TIA
• patients with contraindication of venous thrombolysis
• patients with encephalic bleeding disorder
• patients with incomplete hepatic and renal function
• patients with a medical history of peptic ulcer, haemorrhagic stroke, brain tumour or brain trauma
• patients who could not coordinate with an MRS scan and
• patients with vertebral basilar artery system infarction.